Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

Fort Lauderdale, FL (May 4, 2009): Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosciences, demonstrate the ability of LX211 (LUVENIQ, voclosporin oral capsule) to significantly improve this chronic eye inflammation. Additionally, in patients who are discontinuing potentially toxic medications for uveitis, such as the corticosteroid prednisone, LX211 actively reduces the rate of inflammatory exacerbations by 50% at six months, compared to placebo. The study results also show a safety profile for LX211 at the 0.4 mg/kg bid dose that suggests the experimental drug would be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory eye disease, while also providing a means to greatly reduce the serious health risks associated with long-term corticosteroid use. LX211 is a novel and proprietary next-generation calcineurin inhibitor that Lux Biosciences is developing for ophthalmic uses.

Dr. James T. Rosenbaum, M.D., Professor of Ophthalmology, Medicine and Cell Biology and Vice-Chair of the Department of Ophthalmology of the Casey Eye Institute Oregon Health Sciences University (OHSU), represented the LUMINATE Investigator Network in presenting the Phase 3 LUMINATE program results for the first time at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The LUMINATE program, consisting of three randomized, double-masked, dose-ranging and placebo-controlled trials that enrolled a total of 558 patients at 56 sites in 7 countries (United States, Canada, United Kingdom, France, Germany, Austria and India), is the largest clinical program ever conducted in uveitis.

"Uveitis, a term used to classify a group of autoimmune diseases characterized by chronic inflammation of
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. The first DFG research centers to be funded for another 4 years
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... Space ... the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity ... ... off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific ...
... , Full enrollment occurs five months ahead of schedule , ... /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced ... clinical study of its lead drug RVX-208. "The completion of ... months ahead of our original schedule, is a very exciting ...
... , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... China -based biotechnology company,focused on researching, developing, manufacturing and ... Panacor Bioscience Ltd. to develop and commercialize its,Nephoxil(R) pharmaceutical ...
Cached Biology Technology:Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 2Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 3Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 43SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:4/20/2014)... Neb., April 20, 2014 -- Using corn crop residue ... and can generate more greenhouse gases than gasoline, according ... Nature Climate Change . , The findings by a ... whether corn residue can be used to meet federal ... gas emissions. , Corn stover -- the stalks, leaves ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... For the past 20 years, researchers have published ... research findings have suggested that soil organic carbon can ... tillage systems to no-till systems. However, there is a ... in corn and soybean rotations without cover crops, small ... carbon stocks at the published rates. , "Some studies ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4
... College of Medical Genetics (ACMG) will hold its 16th ... Sunday, March 29, 2009 at the Tampa Convention Center. ... healthcare is evolving at a dizzying pace and the ... opportunity for the medical and scientific media to learn ...
... then eating less may help you live longer. For ... of a new study predict the anti-aging strategy known ... dangerous exercise. "Today there are a lot of very ... this," said Raj Sohal, professor at the University of Southern ...
... A new strategy developed in the Neonatal and Infant ... premature infants and other newborns with severe swallowing difficulties ... study appearing in the February issue of the ... Nationwide Children,s were able to help 15 out of ...
Cached Biology News:Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29 2Eating less may not extend life 2Crib-side studies help struggling newborns go home without feeding tubes 2Crib-side studies help struggling newborns go home without feeding tubes 3
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Biology Products: